Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells

被引:5
|
作者
Nicoletti, MI
Myers, TG
Fojo, T
Blagosklonny, MV
机构
[1] NCI, Med Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Dev Therapeut Program, NIH, Bethesda, MD 20892 USA
关键词
p53; MDR-1; drug resistance;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The notion that wt p53 downregulates MDR-1 links p53 mutations to multidrug resistant phenotype. Alternatively, it has been envisioned that wt p53 protects cells against DNA damaging drugs by inducing MDR-1. Opposing conclusions on the relationship between MDR-1 and p53 have been predominantly based on the effects of p53 on MDR-1 promoter-constructs. We found that introduction of wt p53 slightly induced MDR-1 mRNA in three cell lines having endogenous mt p53. Wt p53-mediated induction of endogenous MDR-1 may represent a rudiment of cellular protection against toxic compounds earlier in evolution. Marked induction of p21(WAF1/CIP1) (p21) mRNA was observed in all cell lines; and lower levels of wt p53 were required to induce p21 than MDR-1. Pgp was undetectable and wt p53 did not increase resistance to an MDR-1 substrate, suggesting the changes in MDR-1 mRNA may be functionally insignificant. Unlike endogenous MDR-1, the expression of an MDR-1 promoter (-434/+147 fragment) - luciferase construct was unchanged or even inhibited by wt p53 that may be secondary to wt p53-mediated cytotoxicity. Thus, partial promoter constructs may not accurately represent endogenous MDR-1.
引用
收藏
页码:375 / 381
页数:7
相关论文
共 50 条
  • [1] Wild-type p53 binds to the human MDR1 promoter
    Strauss, BE
    Haas, M
    FASEB JOURNAL, 1999, 13 (07): : A1480 - A1480
  • [2] Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53
    Jin, X
    Burke, W
    Rothman, K
    Lin, J
    ANTICANCER RESEARCH, 2002, 22 (2A) : 659 - 664
  • [3] Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53
    Li, PX
    Bui, T
    Gray, D
    Klamut, HJ
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 48 (03) : 273 - 286
  • [4] Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53
    Peixiang Li
    Thuy Bui
    Dawn Gray
    Henry J. Klamut
    Breast Cancer Research and Treatment, 1998, 48 : 273 - 286
  • [5] SUPPRESSION OF THE HUMAN MDR1 DOWNSTREAM PROMOTER BY WILD-TYPE AND MUTANT HUMAN P53
    STRAUSS, BE
    HAAS, M
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 182 - 182
  • [6] Wild-Type p53 Regulates Apoptosis of Human Breast Cancer Cells
    Zhang, Xuliang
    Yu, Guozheng
    Cai, Lei
    Jian, Ming
    Cai, Lixia
    Xu, Dong
    DISCOVERY MEDICINE, 2024, 36 (191) : 2445 - 2453
  • [7] Docosahexaenoic Acid Induces Autophagy Through p53/AMPK/mTor Signaling in Human Cancer Cells Harboring Wild-type p53
    Lim, K.
    Jing, K.
    Song, K. S.
    Shin, S.
    Kim, N.
    Jeong, S.
    Heo, J. Y.
    Park, H. D.
    Yoon, W. H.
    Hwang, B. D.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S106 - S106
  • [8] Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status
    Li, HW
    Lochmuller, H
    Yong, VW
    Karpati, G
    Nalbantoglu, J
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (08): : 872 - 878
  • [9] INTRODUCTION OF WILD-TYPE P53 IN A HUMAN OVARIAN-CANCER CELL-LINE NOT EXPRESSING ENDOGENOUS P53
    VIKHANSKAYA, F
    ERBA, E
    DINCALCI, M
    BROGGINI, M
    NUCLEIC ACIDS RESEARCH, 1994, 22 (06) : 1012 - 1017
  • [10] An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53
    Blaszczyk-Thurin, M
    O, I
    Ertl, HCJ
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 56 (04) : 361 - 375